What is GLP-1, and where does it come from?
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by L-cells in the small intestine and colon in response to food intake. It is also produced in the brainstem. Under normal physiology, GLP-1 is released after a meal and persists in the circulation for only a few minutes before being degraded by an enzyme called dipeptidyl peptidase-4 (DPP-4).
GLP-1 receptor agonists are synthetic molecules designed to bind and activate the GLP-1 receptor with a much longer half-life than endogenous GLP-1 — ranging from hours (liraglutide) to roughly a week (semaglutide). This extended activity is what makes them therapeutically useful for weight management: the appetite and satiety effects persist beyond what a natural post-meal GLP-1 spike produces.
How does GLP-1 slow gastric emptying, and why does it matter?
One of the most immediate effects of GLP-1 receptor activation is a slowing of gastric motility — how quickly food moves from the stomach into the small intestine. When the stomach empties more slowly, food stays in the stomach longer, which extends the physical sensation of fullness after a meal.
This effect is most pronounced at lower doses and tends to attenuate somewhat at higher doses. It is also responsible for one of the most common side effects of GLP-1 therapy: nausea, particularly in the early weeks of treatment and during dose escalation. When the stomach is holding food longer than expected, the result can be nausea or a reduced desire to eat again — which contributes to the caloric reduction but can also be uncomfortable.
Gradual dose titration — starting low and increasing slowly over months — is the standard approach to managing this effect and allowing the GI tract to adapt.
Why does GLP-1 reduce hunger, not just fullness?
GLP-1 receptors are expressed in the hypothalamus, particularly in areas involved in appetite regulation — including the arcuate nucleus and the nucleus tractus solitarius. When GLP-1 receptor agonists activate these receptors, the hypothalamus sends signals that reduce the drive to eat.
This is a different mechanism from the gastric emptying effect, and it operates at a more fundamental level. It is not about feeling physically full from food in the stomach — it is about the brain generating less of the biological signal that drives hunger between meals. Patients on GLP-1 therapy frequently describe this as “food noise” quieting: the intrusive thoughts about food, snacking, and the next meal that many people with excess weight experience chronically simply become less intense.
This central appetite suppression is a key reason why GLP-1 receptor agonists produce weight reduction that is meaningfully larger than what patients typically achieve through caloric restriction alone. It removes a significant portion of the physiological pressure that makes dietary restriction so difficult to sustain.
GLP-1 doesn’t burn fat — it quiets the biology of hunger, so the caloric deficit takes far less willpower to hold.
How does GLP-1 reduce food cravings and reward-driven eating?
GLP-1 receptors also appear in the mesolimbic dopamine system — the brain’s reward circuitry. This pathway is involved in the pleasure derived from eating, particularly from highly palatable foods (high-fat, high-sugar combinations). Activation of GLP-1 receptors in this system appears to reduce the hedonic motivation to eat beyond caloric need.
This is clinically significant. A large proportion of excess caloric intake in adults is not driven by hunger — it is driven by the anticipation of reward from eating. If GLP-1 therapy reduces the reward signal, it removes a major driver of overconsumption that willpower alone struggles to counteract. Patients often report not just eating less but wanting to eat less — a qualitatively different experience from dietary restraint.
What does the clinical evidence show for weight management?
The STEP 1 trial (New England Journal of Medicine, 2021) randomized adults with obesity or overweight plus a weight-related comorbidity to once-weekly semaglutide 2.4 mg or placebo, with lifestyle intervention in both groups. At 68 weeks, the semaglutide group achieved a mean weight reduction of approximately 14.9% of body weight versus 2.4% in the placebo group.
Importantly, these results reflect the population average. Individual responses vary substantially — some patients achieve greater reductions, some less. The mechanisms above are the biology underlying the average; a patient’s individual response depends on their baseline GLP-1 receptor sensitivity, diet, activity, and other physiological variables.
Compounded semaglutide — prepared by licensed 503A pharmacies in the USA and prescribed through licensed telehealth providers — contains semaglutide as its active peptide. It is not FDA-approved and is not the same product as Wegovy or Ozempic, but a clinician can prescribe it at doses aligned with published protocols, with no hidden overseas supply chain.
What does GLP-1 therapy not do?
Understanding the mechanism also clarifies the limitations:
- It does not eliminate the need for caloric deficit: The weight loss is still driven by consuming fewer calories than the body expends. GLP-1 makes the deficit easier to maintain by reducing appetite; it does not create the deficit independently.
- It does not guarantee permanent weight loss after stopping: Most of the weight reduction seen in clinical trials reverses after discontinuation if lifestyle changes are not maintained. This is consistent with the physiological nature of obesity, not a failure of the medication.
- It does not work the same way for everyone: Response varies. A clinician-supervised protocol includes regular monitoring and the ability to adjust dosing or treatment approach based on how an individual responds.
Explore the semaglutide overview or the tirzepatide overview to learn about how clinician-supervised protocols are structured at PepScribe.
Frequently asked questions
How does GLP-1 help you lose weight?
GLP-1 receptor agonists help with weight management through three main mechanisms: they slow gastric emptying so you feel fuller longer after eating, they signal the hypothalamus to reduce appetite between meals, and they dampen the reward-driven desire to eat beyond caloric need. The combined effect is a lower spontaneous caloric intake without requiring active willpower to resist hunger.
Does GLP-1 burn fat directly?
GLP-1 receptor agonists do not burn fat directly. They reduce caloric intake through appetite and satiety mechanisms, and the resulting caloric deficit leads the body to draw on stored fat for energy. The fat loss comes from the deficit, not from any direct fat-burning action of GLP-1 itself.
How long does it take for GLP-1 to help with weight loss?
Most patients on clinician-supervised semaglutide or tirzepatide protocols begin noticing appetite changes within the first few weeks. Meaningful weight reduction typically becomes apparent over 12–24 weeks as the dose is titrated upward. Maximum effect is usually seen over 68–72 weeks in clinical trials, though results vary by individual starting weight, adherence, and metabolic profile.
Will I regain weight if I stop a GLP-1 medication?
Clinical trial data show that a meaningful portion of weight lost during GLP-1 therapy is regained after discontinuation, particularly in patients who do not maintain lifestyle changes. This is consistent with obesity being a chronic, physiologically driven condition rather than a discipline failure. Many clinicians approach GLP-1 therapy as a long-term management tool rather than a short course.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is a clinician-prescribed medication prepared by a licensed 503A pharmacy — it is not the same product as Wegovy and cannot be represented as FDA-approved. It is legally available through licensed telehealth providers during FDA-recognized shortage periods and should only be obtained through a licensed domestic pharmacy under a valid prescription.